Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077659 · ClinicalTrials.gov registry record · Phase 2
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
A Phase 2 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03077659: Completed Phase 2 study, sponsored by NanOlogy.
NCT03077659 is a Phase 2 study that has completed, run by NanOlogy. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03077659, a Phase 2 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
Primary Outcome
Treatment Emergent Adverse Events included laboratory assessments, physical examination findings, and vital signs.
Interventions
- DRUG NanoPac®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-10-04 |
| Phase | Phase 2 |
What the finished NCT03077659 record still lists
NCT03077659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which NanoPac® is the first listed.
NCT03077659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03077659 about?
NCT03077659 is a clinical study titled "Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer". Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
What is the current status of trial NCT03077659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-09-06. Estimated completion is 2018-10-04.
What interventions are being tested in trial NCT03077659?
The interventions under investigation include: NanoPac® (DRUG).
Who is sponsoring clinical trial NCT03077659?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03077659's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI